Prenetics Global Limited

NASDAQ:PRE

Medical - Diagnostics & Research

Healthcare
$10.35 +2.19%

+$0.43 today

Market cap
$185.61M
Beta
0.24
P/E (TTM)
-4.9
EPS (TTM)
-$4.18
52W Low $7.18High $23.63

Volume 1.58M

Average 0.22M

PRE Common Stock Repurchased

Cash spent buying back the company's own shares.

Prenetics Global LimitedNASDAQ: PRE

Common Stock Repurchased · Q1 FY2026 · quarter ended Mar 2026

Common stock repurchased turns negative

Q1 FY2026 common stock repurchased was -$13.12M, compared with $0 a year earlier. Trailing-twelve-month common stock repurchased was -$13.12M.

Context

  • Common stock repurchased amounted to 0.0% of revenue in FY2025, down 1.9 pp from a year earlier.
  • Common stock repurchased increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly common stock repurchased holds near -$13.12M or moves back toward the trailing-twelve-month quarterly average of -$3.28M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$13.12M— QoQ
Last fiscal yearDec 2025
$0+100.0% YoY
LTMMar 2026
-$13.12M— YoY
Common Stock Repurchased past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Common Stock Repurchased history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
+100.0%

Common Stock Repurchased vs competitors

How PRE compares with its peers on the latest reported figures

  • PRE's LTM Mar 2026 common stock repurchased of $13.12M is the 2nd largest of the 11 companies compared; the peer median is $0.
  • Common stock repurchased amounts to 11.5% of revenue for PRE, versus a peer median of 0.0%.
PRE Competitors Peer median
Common Stock Repurchased for PRE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OSUROraSure Technologies, Inc.LTM Mar 2026$19.1M -4658.2%+88.3%16.9%
PREPrenetics Global LimitedLTM Mar 2026$13.12M ——11.5%
PROFProfound Medical Corp.LTM Mar 2026$0 ——0.0%
TLSITriSalus Life Sciences, Inc.LTM Mar 2026$0 ——0.0%
ARMPArmata Pharmaceuticals, Inc.LTM Mar 2026$0 +100.0%—0.0%
CDXSCodexis, Inc.LTM Mar 2026$0 ——0.0%
MXCTMaxCyte, Inc.LTM Mar 2026$0 ——0.0%
STIMNeuronetics, Inc.LTM Mar 2026$0 ——0.0%
IMDXInsight Molecular Diagnostics Inc.LTM Mar 2026$0 ——0.0%
ATLNAtlantic International Corp.LTM Dec 2025$0 ——0.0%
SGMOSangamo Therapeutics, Inc.LTM Mar 2026$0 ——0.0%
Peer median (excluding PRE) $0-2279.1%+88.3%0.0%

Competitors are the stored peer set for PRE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(174.02M)(190.45M)(64.78M)(49.81M)(52.7M)
Depreciation & Amortization7.35M7.54M7.79M5.93M3.78M
Deferred Income Tax3.73M7.15M(385.84K)(7.87M)0
Stock-Based Compensation22.49M31.58M10.59M11.98M0
Change in Working Capital(6.59M)(33.76M)24.21M1.97M6.62M
Accounts Receivables(24.06M)6.97M37.63M(428K)(529K)
Inventory(2.33M)1.26M(1.73M)1.32M(3.38M)
Accounts Payables(3.46M)(2.63M)(5.62M)(4.68M)4.91M
Other Working Capital23.26M(39.36M)(6.08M)5.75M5.62M
Other Non-Cash Items160.45M192.46M8.8M8.93M20.48M
Operating Cash Flow13.42M14.51M(13.76M)(28.87M)(21.81M)
Capital Expenditures(11.41M)(6.34M)(911.81K)(1.07M)(208K)
Acquisitions (Net)0(3.42M)021.65M37.78M
Purchases of Investments(10M)(39.92M)(26M)(129K)(20M)
Sales of Investments03M19.92M16M0
Other Investing Activities(3.47M)531.99K(76.52M)2.02M1,000K
Investing Cash Flow(22.02M)(46.14M)(82.95M)38.54M(35.79M)
Debt Repayment(1.3M)(1.88M)(3.23M)(2.56M)40.15M
Common Stock Issued0116.86K2.17K02K
Common Stock Repurchased0(661.52K)(1.23M)(577K)0
Dividends Paid00000
Other Financing Activities4.65M145.86M(241.5K)(203K)(2.61M)
Financing Cash Flow29.32M143.32M(4.7M)(3.34M)37.54M
Effect of Forex Changes87.21K(317.47K)467.93K221K(65K)
Net Change in Cash20.8M111.37M(100.95M)6.55M(20.12M)
Free Cash Flow2M8.17M(14.68M)(29.94M)(22.02M)

Prenetics Global Limited

NASDAQ:PRE

Intrinsic Alpha fair value

Locked

Current Price

$10.35

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.